Operating Leverage Inflection
Expected: Q3 FY26HIGH confidence
What: EBITDA Margin: 35.4%
Impact: 820 bps expansion
Pfizer Ltd: Why Is It Outperforming Nifty 500?
ActiveAverageRe-Entry
In , Pfizer Ltd (Pharma - MNC bulk Drugs) is outperforming Nifty 500 with +6.3% relative strength. Fundamentals: Average.
Pfizer Ltd Key Facts
- PE Ratio
- 29.0x
- Market Cap
- ₹22,045 Cr
- PAT Growth YoY
- +11%
- Revenue Growth YoY
- +20%
- OPM
- 35.0%
- RS vs Nifty 500
- +6.3%
Strong Opportunity
What's Happening
💎PE falling while earnings hold — value emerging
🌐FII stake decreased 0.9% this quarter
🏛️DII accumulation — stake up 1.1%
💰Trading 47% below estimated fair value — significant discount
Earnings Acceleration Triggers
1. Operating Leverage Inflection
Q3 FY26HIGH
2. New Product Or Brand Launch
Short termMEDIUM
Key Risks
1. Loss of exclusivity (LOE) and patent cliffs for major drugs like Eliquis and Ibr
HIGH2. GST tax demands and antitrust settlements
MEDIUMSector-Specific Signals
Eliquis Growth22%22%
Mucaine Growth14%14%
Manufacturing Capacity3.6 billion
Phase 3 Pipeline Assets30
Key Numbers
PAT Growth YoY
+11%
Decelerating
Revenue YoY
+20%
Stable
Operating Margin
35.0%
+800 bps YoY
PE Ratio
29.0
Current Price
₹4,819
Dividend Yield
0.73%
Fundamental Score
52/100
Average
3Y PAT CAGR
+8%
Market Cap
22.0K Cr
Valuation
Significantly Undervalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
Why Are Pfizer Ltd's Earnings Accelerating?
Based on Q3 FY26 (web) earnings • Updated Apr 19, 2026
New Product Or Brand Launch
Expected: Short termMEDIUM confidence
What: Pipeline Assets: Prevenar 20
Impact: Not Given
What Are the Key Risks for Pfizer Ltd?
Earnings deceleration risks from management commentary
Loss of exclusivity (LOE) and patent cliffs for major drugs like Eliquis and Ibr
HIGHTrigger: Loss of exclusivity (LOE) and patent cliffs for major drugs like Eliquis and Ibrance.
Impact: PAT impact: $1.5 billion revenue hit
Management view: Cost-cutting and pipeline investment
Monitor: regulatory
GST tax demands and antitrust settlements
MEDIUMTrigger: GST tax demands and antitrust settlements.
Impact: PAT impact: ₹29.48 lakh GST demand
Management view: Plans to appeal
Monitor: litigation
What Did Pfizer Ltd Report This Quarter?
Headline numbers from the latest earnings call
Revenue
₹645.03 crore
YoY +19.9%QoQ -0.14%
Revenue growth was driven by core therapeutic segments and power brands like Mucaine and Eliquis.
EBITDA
₹228.3 crore
YoY +55.8%Margin 35.4%
EBITDA expansion of 820 basis points was aided by effective cost management and a favorable product mix.
PAT
₹141.84 crore
YoY +11.1%QoQ -24.96%
Net profit growth was moderated by exceptional items of ₹58.20 crore related to a Cipla partnership and labor law changes.
Other Highlights
• Exceptional items of ₹58.20 crore recognized for Q3 FY26.
• Total income for the quarter reached ₹683.24 crore.
• Earnings per share grew to ₹31.01 from ₹27.89 YoY.
What Sector Metrics Matter for Pfizer Ltd?
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
Eliquis Growth
22%
YoY 22%
Why: Strong performance in the CVS segment as per IQVIA data.
Mucaine Growth
14%
YoY 14%
Why: Steady demand in the antacid category.
Manufacturing Capacity
3.6 billion
Why: Stable run rate at the Goa facility.
Phase 3 Pipeline Assets
30
Why: Reflects global R&D focus on oncology and innovative medicines.
What Is Pfizer Ltd's Management Guidance?
Forward-looking targets from management for FY26
OPM Guidance
27.8%
Revenue Outlook
$59.5 to $62.5 Billion (Global)
Margin Outlook
Anticipated stable gross and operating margins
Capex Plan
$10.5 to $11.5 Billion
R&D Expenses
Volume
Operational revenue growth excluding COVID and LOE
Management Tone: CAUTIOUS
Guidance Changes
LOWERED
Revenue: $61.0 – $64.0 billion → Approximately $62.0 billion
Lower COVID vaccine sales and patent expirations
How Fast Is Pfizer Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +20% | -4% | Stable |
| PAT (Net Profit) | +11% | +8% | Decelerating |
| OPM | 35.0% | +800 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 19, 2026.
Other Top Pharma - MNC bulk Drugs Stocks Beating Nifty 500
Frequently Asked Questions: Pfizer Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were Pfizer Ltd's latest quarterly results?
Pfizer Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +10.9% (decelerating)
- Revenue Growth YoY: +19.9%
- Operating Margin: 35.0% (volatile)
Is Pfizer Ltd's profit growing or declining?
Pfizer Ltd's profit is growing with an decelerating trend.
- PAT Growth YoY: +10.9% (latest quarter)
- PAT Growth QoQ: -24.9% (sequential)
- 3-Year PAT CAGR: +7.8%
- Trend: Decelerating — growth rate slowing from prior quarter
What is Pfizer Ltd's revenue growth trend?
Pfizer Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +19.9%
- Revenue Growth QoQ: +0.5% (sequential)
- 3-Year Revenue CAGR: -4.4%
How is Pfizer Ltd's operating margin trending?
Pfizer Ltd's operating margin is volatile.
- Current OPM: 35.0%
- OPM Change YoY: +8.0% basis points
- OPM Change QoQ: -1.0% basis points
What is Pfizer Ltd's 3-year profit and revenue CAGR?
Pfizer Ltd's long-term compounding rates
- 3-Year Profit CAGR: +7.8%
- 3-Year Revenue CAGR: -4.4%
Is Pfizer Ltd's growth accelerating or decelerating?
Pfizer Ltd's earnings growth is decelerating with negative momentum on a sequential basis.
- YoY Acceleration: -8.7% bps
- Sequential Acceleration: -23.3% bps
What is Pfizer Ltd's trailing twelve month (TTM) performance?
Pfizer Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹854 Cr
- TTM PAT Growth: +38.6% YoY
- TTM Revenue: ₹2,000 Cr
- TTM Revenue Growth: +10.9% YoY
- TTM Operating Margin: 36.0%
Is Pfizer Ltd overvalued or undervalued?
Pfizer Ltd appears significantly undervalued based on our fair value analysis.
- Valuation Signal: Significantly Undervalued
- Current PE: 29.0x
- Price-to-Book: 5.7x
What is Pfizer Ltd's current PE ratio?
Pfizer Ltd's current PE ratio is 29.0x.
- Current PE: 29.0x
- Market Cap: 22.0K Cr
- Dividend Yield: 0.73%
How does Pfizer Ltd's valuation compare to its history?
Pfizer Ltd's current PE is 29.0x.
- Current PE: 29.0x
- Valuation Assessment: Significantly Undervalued
What is Pfizer Ltd's price-to-book ratio?
Pfizer Ltd's price-to-book ratio is 5.7x.
- Price-to-Book (P/B): 5.7x
- Book Value per Share: ₹841
- Current Price: ₹4819
Is Pfizer Ltd a fundamentally strong company?
Pfizer Ltd is rated Average with a fundamental score of 52.27/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +19.9% (10% weight)
- PAT Growth YoY: +10.9% (10% weight)
- PAT Growth QoQ: -24.9% (10% weight)
- Margins stable (10% weight)
Is Pfizer Ltd debt free?
Pfizer Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹43 Cr
What is Pfizer Ltd's return on equity (ROE) and ROCE?
Pfizer Ltd's return ratios over recent years
- FY2023: ROCE 26.0%
- FY2024: ROCE 22.0%
- FY2025: ROCE 22.0%
Is Pfizer Ltd's cash flow positive?
Pfizer Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹660 Cr
- Free Cash Flow (FCF): ₹589 Cr
- CFO/PAT Ratio: 86% (strong cash conversion)
What is Pfizer Ltd's dividend yield?
Pfizer Ltd's current dividend yield is 0.73%.
- Dividend Yield: 0.73%
- Current Price: ₹4819
Who holds Pfizer Ltd shares — promoters, FII, DII?
Pfizer Ltd's shareholding pattern (Mar 2026)
- Promoters: 63.9%
- FII (Foreign): 2.8%
- DII (Domestic): 16.9%
- Public: 16.4%
Is promoter holding increasing or decreasing in Pfizer Ltd?
Pfizer Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 63.9% (Mar 2026)
- Previous Quarter: 63.9% (Dec 2025)
- Change: 0.00% (stable)
How long has Pfizer Ltd been outperforming Nifty 500?
Pfizer Ltd has been outperforming Nifty 500 for 1 consecutive week, indicating early-stage outperformance.
Is Pfizer Ltd a new momentum entry or an established outperformer?
Pfizer Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
What are the growth catalysts for Pfizer Ltd?
Pfizer Ltd has 2 key growth catalysts identified from recent earnings analysis
- Operating Leverage Inflection — Significant margin expansion despite moderate PAT growth.
- New Product Or Brand Launch — New launches are critical to offset the patent cliff of older blockbusters.
What are the key risks in Pfizer Ltd?
Pfizer Ltd has 2 key risks worth monitoring
- [HIGH] Loss of exclusivity (LOE) and patent cliffs for major drugs like Eliquis and Ibr — Loss of exclusivity (LOE) and patent cliffs for major drugs like Eliquis and Ibrance.
- [MEDIUM] GST tax demands and antitrust settlements — GST tax demands and antitrust settlements.
What is Pfizer Ltd's management guidance for growth?
Pfizer Ltd's management has provided the following forward guidance for FY26
- Revenue outlook: $59.5 to $62.5 Billion (Global)
- OPM guidance: 27.8%
- Capex plan: $10.5 to $11.5 Billion for R&D Expenses
- Management tone: cautious
- Milestone: [LOWERED] Revenue: $61.0 – $64.0 billion → Approximately $62.0 billion
What sector-specific metrics matter most for Pfizer Ltd?
Pfizer Ltd's most important sub-sector-specific KPIs from the latest concall
- Eliquis Growth: 22% (YoY 22%) — Strong performance in the CVS segment as per IQVIA data.
- Mucaine Growth: 14% (YoY 14%) — Steady demand in the antacid category.
- Manufacturing Capacity: 3.6 billion — Stable run rate at the Goa facility.
- Phase 3 Pipeline Assets: 30 — Reflects global R&D focus on oncology and innovative medicines.
Is Pfizer Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Pfizer Ltd may be worth studying
- Earnings growing at +10.9% YoY
- Valuation: appears significantly undervalued
- Cash flow is positive — CFO ₹660 Cr
What is the investment thesis for Pfizer Ltd?
Pfizer Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +19.9% YoY
- Appears significantly undervalued
- Growth catalyst: Operating Leverage Inflection
Risk Factors (Bear Case)
- Earnings growth decelerating
- Key risk: Loss of exclusivity (LOE) and patent cliffs for major drugs like Eliquis and Ibr
What is the future outlook for Pfizer Ltd?
Pfizer Ltd's forward outlook based on current data signals
- Earnings Trend: decelerating
- Revenue Trend: stable
- Margin Trend: volatile
- Valuation: Significantly Undervalued
- Key Catalyst: Operating Leverage Inflection
- Key Risk: Loss of exclusivity (LOE) and patent cliffs for major drugs like Eliquis and Ibr
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.